Haemonetics Corporation
Haemonetics Corporation Fundamental Analysis
Haemonetics Corporation (HAE) shows weak financial fundamentals with a PE ratio of 27.20, profit margin of 7.29%, and ROE of 11.32%. The company generates $1.3B in annual revenue with weak year-over-year growth of -1.97%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze HAE's fundamental strength across five key dimensions:
Efficiency Score
WeakHAE struggles to generate sufficient returns from assets.
Valuation Score
ModerateHAE shows balanced valuation metrics.
Growth Score
WeakHAE faces weak or negative growth trends.
Financial Health Score
ModerateHAE shows balanced financial health with some risks.
Profitability Score
WeakHAE struggles to sustain strong margins.
Key Financial Metrics
Is HAE Expensive or Cheap?
P/E Ratio
HAE trades at 27.20 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, HAE's PEG of -0.70 indicates potential undervaluation.
Price to Book
The market values Haemonetics Corporation at 3.32 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 4.98 times EBITDA. This is generally considered low.
How Well Does HAE Make Money?
Net Profit Margin
For every $100 in sales, Haemonetics Corporation keeps $7.29 as profit after all expenses.
Operating Margin
Core operations generate 18.15 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.32 in profit for every $100 of shareholder equity.
ROA
Haemonetics Corporation generates $4.06 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Haemonetics Corporation produces operating cash flow of $294.79M, showing steady but balanced cash generation.
Free Cash Flow
Haemonetics Corporation generates strong free cash flow of $261.83M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $5.63 in free cash annually.
FCF Yield
HAE converts 9.86% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.20
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.70
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.54
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.95
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How HAE Stacks Against Its Sector Peers
| Metric | HAE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.20 | 28.65 | Neutral |
| ROE | 11.32% | 795.00% | Weak |
| Net Margin | 7.29% | -49787.00% (disorted) | Weak |
| Debt/Equity | 1.54 | 0.40 | Weak (High Leverage) |
| Current Ratio | 2.95 | 3.73 | Strong Liquidity |
| ROA | 4.06% | -20255.00% (disorted) | Weak |
HAE outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Haemonetics Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
64.65%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
31.55%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
189.54%
Industry Style: Defensive, Growth, Innovation
High Growth